In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and infection prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Last trade$87.00
Day change-$1.65 (-1.86%)
Day range$74.45 – $88.88
Volume313,779
Market cap$15.05B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.05B
Price / earnings
96.46×
Price / book
3.13×
Price / sales
1.84×
EV / sales
2.43×
EV / EBITDA
-34.62×
Profitability
Earnings per share
$0.92
Return on assets
1.1%
Return on equity
3.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.1×
Current ratio
1.03×
Quick ratio
0.72×
Cash ratio
0.13×
Cash flow
Price / cash flow
48.54×
Price / free cash flow
—
Free cash flow
$0
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SOLV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.95B
$2.21B
$2.01B
$2B
$2.1B
$2.16B
$2.07B
$2.08B
Cost of revenue
$887M
$923M
$910M
$971M
$961M
$986M
$956M
$956M
Gross profit
$1.06B
$1.29B
$1.1B
$1.03B
$1.14B
$1.18B
$1.11B
$1.12B
Selling, general and administrative
$813M
$927M
$827M
$759M
$780M
$772M
$769M
$784M
Research and development
$181M
$178M
$189M
$175M
$183M
$189M
$193M
$199M
Total operating expenses
$994M
$1.11B
$1.02B
$2.45B
$963M
$961M
$962M
$983M
Operating income
$68M
$181M
$81M
-$1.43B
$172M
$214M
$152M
$136M
Interest expense
-$68M
-$64M
-$62M
$0
-$89M
-$103M
-$104M
$0
Income before taxes
-$11M
$108M
$16M
$58M
$1.51B
$103M
$38M
$13M
Income taxes
$1M
$15M
$3M
-$5M
$248M
$13M
-$99M
-$17M
Net income
-$12M
$93M
$13M
$63M
$1.27B
$90M
$137M
$30M
Net income attributable to common shareholders
-$12M
$92M
$13M
$63M
$1.27B
$90M
$137M
$31M
EBITDA
$204M
$314M
$216M
-$1.31B
$293M
$336M
$281M
$286M
Basic earnings per share
-$0.07
$0.53
$0.07
$0.36
$7.26
$0.52
$0.79
$0.18
Diluted earnings per share
-$0.07
$0.53
$0.07
$0.36
$7.22
$0.51
$0.78
$0.18
Recent news
Company coverage with links to the original publishers.
Solventum Corporation (SOLV), a healthcare company spun off from 3M, has received a #2 (Buy) rating on the Zacks Rank with a B VGM Score. The stock has shown positive momentum with a 1.6% gain over four weeks, and five analysts have revised earnings estimates upward for fiscal 2026, increasing the consensus estimate to $7.29 per share.
Solventum reported Q3 2026 revenue of $1.95 billion, down 7% year-over-year, slightly missing the $1.97 billion consensus estimate. However, EPS of $1.45 beat expectations with a +7.41% surprise versus the $1.35 estimate. The company showed mixed performance across segments, with MedSurg and Health Information Systems posting modest gains, while Dental Solutions declined 6.8%. The stock has a Zacks Rank #3 (Hold) rating.
Solventum reported Q3 2026 earnings of $1.45 per share, beating consensus estimates of $1.35 by 7.41%, but revenues of $1.95 billion missed expectations by 1.07%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Services industry ranks in the top 45% of Zacks industries.
Solventum (SOLV) is well-positioned for growth with strong Q2 2026 performance, a $500M cost-saving transformation program, and 18% projected earnings growth for 2026. However, the company faces potential margin headwinds from a 3M supply agreement that could increase raw material costs by up to 100 basis points in 2027.
Solventum (SOLV) is set to report Q3 2026 earnings on Nov. 5 with projected 8% earnings decline and 6% revenue decline. While MedSurg and Dental segments show strong momentum and Acera demonstrates 48% Q2 growth, the company faces headwinds from a $125M ERP-related order reversal, tariff pressures, and margin compression. Despite challenges, Zacks' model predicts an earnings beat with a +10.15% Earnings ESP and Rank #3 rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.